EA201071316A1 - Иммуномодуляция ингибиторами ингибиторов апоптоза - Google Patents

Иммуномодуляция ингибиторами ингибиторов апоптоза

Info

Publication number
EA201071316A1
EA201071316A1 EA201071316A EA201071316A EA201071316A1 EA 201071316 A1 EA201071316 A1 EA 201071316A1 EA 201071316 A EA201071316 A EA 201071316A EA 201071316 A EA201071316 A EA 201071316A EA 201071316 A1 EA201071316 A1 EA 201071316A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
methods
treating
immunomodulation
apoptosis
Prior art date
Application number
EA201071316A
Other languages
English (en)
Inventor
Лей Зэйвел
Кристофер С. Страуб
Брант Дж. Файрстоун
Глен Дранофф
Майкл Дуган
Original Assignee
Новартис Аг
Дана Фарбер Кэнсер Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40823320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071316(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг, Дана Фарбер Кэнсер Инститьют, Инк. filed Critical Новартис Аг
Publication of EA201071316A1 publication Critical patent/EA201071316A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается иммуностимуляторов, содержащих ингибиторы ИА, включая миметики белка Smac. Изобретение предлагает также лекарственные препараты и вакцины, содержащие ингибитор ИА и антиген. Описаны также способы усиления иммунной реакции введением ингибитора ИА, способы лечения и профилактики рака, способы лечения и профилактики инфекционных заболеваний, способы лечения аутоиммунных нарушений и способы усиления производства цитокинов или антител.
EA201071316A 2008-05-16 2009-05-14 Иммуномодуляция ингибиторами ингибиторов апоптоза EA201071316A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5394708P 2008-05-16 2008-05-16
PCT/US2009/043874 WO2009140447A1 (en) 2008-05-16 2009-05-14 Immunomodulation by iap inhibitors

Publications (1)

Publication Number Publication Date
EA201071316A1 true EA201071316A1 (ru) 2011-06-30

Family

ID=40823320

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071316A EA201071316A1 (ru) 2008-05-16 2009-05-14 Иммуномодуляция ингибиторами ингибиторов апоптоза

Country Status (17)

Country Link
US (4) US9750729B2 (ru)
EP (3) EP3701947A1 (ru)
JP (3) JP5779091B2 (ru)
KR (1) KR20110022608A (ru)
CN (1) CN102099035A (ru)
AU (1) AU2009246347A1 (ru)
BR (1) BRPI0912692A2 (ru)
CA (1) CA2724720A1 (ru)
CL (1) CL2009001195A1 (ru)
EA (1) EA201071316A1 (ru)
ES (2) ES2791957T3 (ru)
IL (1) IL209203A0 (ru)
MA (1) MA32388B1 (ru)
MX (1) MX2010012231A (ru)
TW (1) TW201006834A (ru)
WO (1) WO2009140447A1 (ru)
ZA (1) ZA201008176B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
EP1951698A4 (en) 2005-10-25 2010-04-28 Aegera Therapeutics Inc BINDING COMPOUNDS TO THE IAP BIR DOMAIN
JP4995211B2 (ja) * 2008-09-29 2012-08-08 キヤノン株式会社 電子写真画像形成装置
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10781205B2 (en) * 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
EP3831811A4 (en) * 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
EP4034102A1 (en) 2019-09-25 2022-08-03 Debiopharm International SA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
ES2415336T3 (es) * 2003-04-11 2013-07-25 Survac Aps Vacuna terapéutica contra el cáncer
WO2005077969A2 (en) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005084317A2 (en) 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
EP1740173A4 (en) * 2004-03-23 2009-05-27 Genentech Inc AZABICYCLOOCTAN IAP INHIBITORS
CN1964970B (zh) 2004-04-07 2011-08-03 诺瓦提斯公司 Iap的抑制剂
KR100760739B1 (ko) 2004-05-02 2007-09-21 가부시키가이샤 세가 게임 시스템, 게임 시스템의 제어 방법 및 컴퓨터 판독가능 기록 매체
AU2006216450C1 (en) 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors
WO2007075525A2 (en) 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110218A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
US20100316573A1 (en) * 2006-10-19 2010-12-16 Larry Alexander Gaither Organic Compounds
US8492429B2 (en) 2006-11-28 2013-07-23 Novartis Ag Combination of IAP inhibitors and FLT3 inhibitors
WO2008077969A1 (en) 2006-12-26 2008-07-03 Arcelik Anonim Sirketi A washer / dryer with output from humidity sensor selectively input to control unit
WO2008109057A1 (en) * 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Organic compounds and their uses

Also Published As

Publication number Publication date
IL209203A0 (en) 2011-01-31
WO2009140447A1 (en) 2009-11-19
CN102099035A (zh) 2011-06-15
CL2009001195A1 (es) 2010-06-11
JP6030739B2 (ja) 2016-11-24
TW201006834A (en) 2010-02-16
JP5986655B2 (ja) 2016-09-06
US20110135691A1 (en) 2011-06-09
AU2009246347A1 (en) 2009-11-19
EP2296650A1 (en) 2011-03-23
EP3701947A1 (en) 2020-09-02
US11382905B2 (en) 2022-07-12
US10786491B2 (en) 2020-09-29
CA2724720A1 (en) 2009-11-19
EP2698158B1 (en) 2021-06-30
JP2011524339A (ja) 2011-09-01
US20220296581A1 (en) 2022-09-22
EP2296650B1 (en) 2020-05-06
MA32388B1 (fr) 2011-06-01
US20200345714A1 (en) 2020-11-05
MX2010012231A (es) 2011-02-18
ES2791957T3 (es) 2020-11-06
US9750729B2 (en) 2017-09-05
EP2698158A1 (en) 2014-02-19
ZA201008176B (en) 2011-08-31
US20170368047A1 (en) 2017-12-28
KR20110022608A (ko) 2011-03-07
JP2015129170A (ja) 2015-07-16
BRPI0912692A2 (pt) 2017-03-21
ES2882855T3 (es) 2021-12-02
JP5779091B2 (ja) 2015-09-16
JP2016094429A (ja) 2016-05-26

Similar Documents

Publication Publication Date Title
EA201071316A1 (ru) Иммуномодуляция ингибиторами ингибиторов апоптоза
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA201790413A1 (ru) Антитела против tigit
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
MX2012010793A (es) Composiciones y metodos para la eliminacion de biopeliculas.
UA106640C2 (uk) Bcl-2-СЕЛЕКТИВНИЙ АПОПТОЗІНДУКУЮЧИЙ ЗАСІБ ДЛЯ ЛІКУВАННЯ РАКУ І ІМУННИХ ЗАХВОРЮВАНЬ
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201270722A1 (ru) Формы рифаксимина и их применение
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EA201300131A1 (ru) Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
EA201391199A1 (ru) Композиции из hyr1-производных и способы лечения ими